Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00638690 · ClinicalTrials.gov registry record · Phase 3
Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
A Phase 3 study of Prostatic Neoplasms, sponsored by Cougar Biotechnology.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,195
- Enrollment target
- 20
- Study locations
NCT00638690 is a Phase 3 study of Prostatic Neoplasms that has completed, run by Cougar Biotechnology. The registered enrollment target is 1,195 participants, above the 496-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (141% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT00638690, a Phase 3 study of Prostatic Neoplasms, has completed, sponsored by Cougar Biotechnology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,195 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer (CRPC) who have failed one or two chemotherapy regimens. At least one of the previous chemotherapies must have contained docetaxel.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Abiraterone acetate
- DRUG Prednisone/prednisolone
Study Locations (20)
California
- - Beverly Hills
- - Duarte
- - Los Angeles
- - Marina del Rey
- - Sacramento
- - San Diego
- - San Francisco
Florida
- - Boca Raton
- - Fort Lauderdale
- - Fort Myers
- - West Palm Beach
Connecticut
- - Bristol
- - New Haven
- - Stamford
Alabama
- - Birmingham
Arizona
- - Tucson
Colorado
- - Aurora
Georgia
- - Atlanta
Hawaii
- - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,195 participants |
| Start Date | 2008-05 |
| Est. Completion | 2012-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00638690
The ClinicalTrials.gov registry entry for NCT00638690 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,195 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 496-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (141% higher). The listed sponsor is Cougar Biotechnology, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostatic Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00638690 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00638690 about?
NCT00638690 is a clinical study titled "Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy". This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer (CRPC) who have failed one or two chemotherapy regimens. At least one of the previous chemotherapies must have ...
What is the current status of trial NCT00638690?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,195 participants. The study started on 2008-05. Estimated completion is 2012-10.
What conditions does trial NCT00638690 study?
This clinical trial studies the following conditions: Prostatic Neoplasms.
What interventions are being tested in trial NCT00638690?
The interventions under investigation include: Placebo (DRUG), Abiraterone acetate (DRUG), Prednisone/prednisolone (DRUG).
Who is sponsoring clinical trial NCT00638690?
This trial is sponsored by Cougar Biotechnology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00638690 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
RECRUITING · Phase 3
-
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
RECRUITING · Phase 3
-
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
RECRUITING · Phase 3
-
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
ACTIVE NOT RECRUITING · Phase 3
-
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.